Innovation Ranking in France and Italy: Differences and their Impact on Pricing and Reimbursement Processes.
نویسندگان
چکیده
& Reimbursement All analyses and interpretations of the data are solely those of the authors and do not refl ect the positions or policies of PHMR Ltd. Contact: Mark Ratcliffe, Managing Director, PHMR Ltd., Berkeley Works, Berkley Grove, London, United Kingdom NW1 8XY Offi ce Tel: +44 (0)2036 955 800. E-mail: [email protected]. • To investigate differences between therapeutic innovation criteria used in Italy and France to evaluate new drugs. • To assess their implications on pricing (ex-factory) and reimbursement.
منابع مشابه
Assessing Patient Organization Participation in Health Policy: A Comparative Study in France and Italy
Background Even though there are many patient organizations across Europe, their role in impacting health policy decisions and reforms has not been well documented. In line with this, the present study endeavours to fill this gap in the international literature. To this end, it aims to validate further a previously developed instrument (the Health Democracy Index - HDI) measuring patient organi...
متن کاملمقایسه نظام قیمت گذاری و بیمه دارو در ایران و کشورهای منتخب
Introduction: Pharmaceuticals comprise a large portion of health care expenditures, including insurance organizations expenditures. Accumulated evidence suggests that the inefficiencies of Iran's health insurance structure have led to soaring out- of- pocket payments by the beneficiaries of health insurance organizations. This study was conducted to compare pricing and reimbursement of pharmace...
متن کاملComparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
Recently, the need for health care services has increased gradually and the limitations in sources allocated for this area have been recognized. Moving from this fact, it has gained a supreme importance to determine what health programs or technologies will be given priority. According to Danzon (Reference pricing: theory and evidence, reference pricing and pharmaceutical policy: perspectives o...
متن کاملPricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.
The main objective of this comparative analysis was to assess regulations applied by EU governments to reward potentially innovative drugs. We focused on the pharmaceutical policy for in-patent drugs in seven EU countries: Belgium, France, Germany, Italy, the Netherlands, Spain, and the UK. A common scheme was applied to all seven countries: first, pricing and reimbursement procedures for new a...
متن کاملProposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
In Poland, two proposed amendments to the reimbursement act are currently in preparation; these are likely to substantially change the pricing and reimbursement landscape for both drugs and medical devices. Proposed changes include: alignment of medical device reimbursement with that of pharmaceuticals; relaxing the strict reimbursement criteria for ultra-orphan drugs; establishment of an addit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 18 7 شماره
صفحات -
تاریخ انتشار 2015